Gotham Asset Management LLC raised its position in Coherus BioSciences, Inc. (NASDAQ:CHRS) by 10.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,380 shares of the biotechnology company’s stock after buying an additional 3,398 shares during the period. Gotham Asset Management LLC owned approximately 0.07% of Coherus BioSciences worth $769,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. State Board of Administration of Florida Retirement System increased its position in Coherus BioSciences by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 14,589 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 130 shares during the last quarter. Nationwide Fund Advisors increased its position in Coherus BioSciences by 1.3% in the first quarter. Nationwide Fund Advisors now owns 33,982 shares of the biotechnology company’s stock valued at $719,000 after buying an additional 421 shares during the last quarter. Legal & General Group Plc increased its position in Coherus BioSciences by 15.9% in the first quarter. Legal & General Group Plc now owns 8,295 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,137 shares during the last quarter. Pictet Asset Management Ltd. increased its position in Coherus BioSciences by 0.3% in the first quarter. Pictet Asset Management Ltd. now owns 441,788 shares of the biotechnology company’s stock valued at $9,344,000 after buying an additional 1,432 shares during the last quarter. Finally, Teachers Advisors LLC increased its position in Coherus BioSciences by 1.6% in the fourth quarter. Teachers Advisors LLC now owns 147,753 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,374 shares during the last quarter. 73.35% of the stock is owned by institutional investors and hedge funds.

Shares of Coherus BioSciences, Inc. (NASDAQ CHRS) traded down 0.78% during midday trading on Thursday, reaching $12.75. The company’s stock had a trading volume of 548,371 shares. Coherus BioSciences, Inc. has a 12 month low of $12.45 and a 12 month high of $31.98. The stock’s market capitalization is $653.92 million. The stock’s 50 day moving average is $14.27 and its 200 day moving average is $20.24.

Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Monday, May 8th. The biotechnology company reported ($1.54) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.54). The company had revenue of $0.16 million for the quarter. Coherus BioSciences had a negative net margin of 76.85% and a negative return on equity of 827.65%. On average, analysts forecast that Coherus BioSciences, Inc. will post ($5.13) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Coherus BioSciences, Inc. (CHRS) Shares Bought by Gotham Asset Management LLC” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/08/03/coherus-biosciences-inc-chrs-stake-boosted-by-gotham-asset-management-llc-updated-updated-updated.html.

Several equities analysts recently weighed in on the company. Credit Suisse Group reaffirmed an “outperform” rating and issued a $24.00 price objective (down from $38.00) on shares of Coherus BioSciences in a research note on Wednesday, June 14th. ValuEngine downgraded Coherus BioSciences from a “hold” rating to a “sell” rating in a research note on Tuesday, June 13th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Coherus BioSciences in a research note on Monday, June 12th. Citigroup Inc. lowered their target price on Coherus BioSciences from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, June 13th. Finally, Cowen and Company reiterated an “outperform” rating and set a $45.00 target price on shares of Coherus BioSciences in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Coherus BioSciences has an average rating of “Buy” and a consensus price target of $37.11.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Institutional Ownership by Quarter for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Stock Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related stocks with our FREE daily email newsletter.